Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yong-Feng Yu

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|January 30, 2013
Maintenance Therapy for NSCLC: Consensus and ControversyShun Lu, Yong-Feng Yu
Zhonghua Yi Xue Za Zhi|December 4, 2009
[Comparison of single-agent docetaxel versus docetaxel plus platinum combination agent in second-line treatment for advanced non-small cell lung cancer]Yi-Fei Zhang, Yong-Feng Yu, Shun Lu
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|January 28, 2006
[Advances in the molecular target therapy in lung cancer]Shun Lu, Yong-feng Yu, Z i-ming Li
Chinese Medical Journal|September 22, 2011
Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatmentZheng-bo Song, Yong-feng Yu, Zhi-wei Chen, et al.
Current Therapeutic Research, Clinical and Experimental|April 1, 2014
The effects of cetuximab alone and in combination with endostatin on vascular endothelial growth factor and interleukin-8 expression in human lung adenocarcinoma cellsYong-Feng Yu, Zhi-Wei Chen, Zi-Ming Li, et al.
Frontiers in Oncology|December 31, 2021
Modelled Economic Analysis for Dacomitinib-A Cost Effectiveness Analysis in Treating Patients With EGFR-Mutation-Positive Non-Small Cell Lung Cancer in ChinaYong-Feng Yu, Luan Luan, Fan-Fan Zhu, et al.
Chemotherapy|November 25, 2010
A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in ChinaYong-feng Yu, Zhi-wei Chen, Zhen Zhou, et al.
Zhonghua Yi Xue Za Zhi|October 10, 2007
[Incidence, time trend, survival, and predictive factors of lung cancer in Shanghai populations]Mei-lin Liao, Zhi-wei Chen, Ying Zheng, et al.
American Journal of Translational Research|March 25, 2017
XBP1-LOX Axis is critical in ER stress-induced growth of lung adenocarcinoma in 3D cultureYi Yang, Bai-Jun Cheng, Hong Jian, et al.
Oncology Reports|September 30, 2010
Discrepancy of biologic behavior influenced by bone marrow derived cells in lung cancerJie Zhang, Xiao-Min Niu, Mei-Lin Liao, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|January 30, 2013
Maintenance Therapy for NSCLC: Consensus and ControversyShun Lu, Yong-Feng Yu
Zhonghua Yi Xue Za Zhi|December 4, 2009
[Comparison of single-agent docetaxel versus docetaxel plus platinum combination agent in second-line treatment for advanced non-small cell lung cancer]Yi-Fei Zhang, Yong-Feng Yu, Shun Lu
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|January 28, 2006
[Advances in the molecular target therapy in lung cancer]Shun Lu, Yong-feng Yu, Z i-ming Li
Chinese Medical Journal|September 22, 2011
Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatmentZheng-bo Song, Yong-feng Yu, Zhi-wei Chen, et al.
Current Therapeutic Research, Clinical and Experimental|April 1, 2014
The effects of cetuximab alone and in combination with endostatin on vascular endothelial growth factor and interleukin-8 expression in human lung adenocarcinoma cellsYong-Feng Yu, Zhi-Wei Chen, Zi-Ming Li, et al.
Frontiers in Oncology|December 31, 2021
Modelled Economic Analysis for Dacomitinib-A Cost Effectiveness Analysis in Treating Patients With EGFR-Mutation-Positive Non-Small Cell Lung Cancer in ChinaYong-Feng Yu, Luan Luan, Fan-Fan Zhu, et al.
Chemotherapy|November 25, 2010
A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in ChinaYong-feng Yu, Zhi-wei Chen, Zhen Zhou, et al.
Zhonghua Yi Xue Za Zhi|October 10, 2007
[Incidence, time trend, survival, and predictive factors of lung cancer in Shanghai populations]Mei-lin Liao, Zhi-wei Chen, Ying Zheng, et al.
American Journal of Translational Research|March 25, 2017
XBP1-LOX Axis is critical in ER stress-induced growth of lung adenocarcinoma in 3D cultureYi Yang, Bai-Jun Cheng, Hong Jian, et al.
Oncology Reports|September 30, 2010
Discrepancy of biologic behavior influenced by bone marrow derived cells in lung cancerJie Zhang, Xiao-Min Niu, Mei-Lin Liao, et al.
Pageof 1